Frontlight ResearchEarly access
Active, not recruitingPhase 2
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
Key facts
- Who runs it
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Where
- Richmond, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 25 people enrolled
- Started
- 2 Nov 2023
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Albumin Infusion
- Record updated
- 25 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Age >18 years
- Cirrhosis diagnosed using either (a) liver biopsy, (b) transient wave elastography (>20 KPa) (c) radiological evidence consistent with cirrhosis, (d) in a patient with chronic liver disease endoscopic or radiological evidence of varices (e), in a patient with chronic liver disease, platelet count <150,000/mm3 and AST/ALT ratio >1
- Cognitive impairment defined by MHE on psychometric hepatic encephalopathy score (PHES), critical flicker frequency (CFF), or EncephalApp Stroop
- Prior HE controlled by lactulose or rifaximin for at least one month
- Serum albumin <4gm/dl
Who cannot take part
- No prior overt HE
- No cognitive impairment on the tests noted
- Infection within a month
- Congestive heart failure
- Requiring regular albumin infusions within 3 months or anticipated during the study visit
- Allergies to albumin
- Serum albumin >4gm/dl
- Unclear diagnosis of cirrhosis
- Unlikely to be adherent to the study
- Unable or unwilling to consent
- West Haven Criteria>2
- Alcohol abuse within 1 month
Where in United States
- Hunter Holmes McGuire VA Medical CenterRichmond, United States
About the trial
What the trial wants to find out
Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial changes.
Read full original descriptionShow less
This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over 8 weeks with biological sampling and cognitive and health related quality of life (HRQOL) testing with each subject acting as their own control.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
Saline given at the same volume as the albumin on visits the patients are assigned to it
Treatment: Albumin Infusion
- AlbuminExisting treatment, for comparison
IV Albumin at 1.5g/kg ideal body weight
Treatment: Albumin Infusion
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Clinical Trial in Hepatic Encephalopathy to Study Lasting Cognitive Improvement With Intravenous Albumin
- Record updated
- 25 August 2026